1
-
3
of
3
results (0.28 seconds)
Sort By:
-
Biosimilars, Part 3: Humira Biosimilar Launches
Biosimilars, Part 3: Humira Biosimilar Launches The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The ...- Authors: Tony Pistilli, Greg Warren
- Date: Nov 2023
- Competency: External Forces & Industry Knowledge; Strategic Insight and Integration
- Publication Name: Health Watch
- Topics: Health & Disability; Health & Disability>Health care; Health & Disability>Health insurance; Public Policy; Public Policy; Public Policy
-
Biosimilars, Part 4: The Financial Impact
Biosimilars, Part 4: The Financial Impact Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can ...- Authors: Greg Warren, Tony Pistilli
- Date: Nov 2023
- Competency: External Forces & Industry Knowledge; Strategic Insight and Integration
- Publication Name: Health Watch
- Topics: Health & Disability; Health & Disability>Health care; Health & Disability>Health insurance; Public Policy; Public Policy; Public Policy
-
PBM Issues
PBM Issues PBMs are positioned in the healthcare delivery system as the only entity that is not regulated for profitability. The Commercial Fully Insured Health Insurance Plans are heavily ...- Authors: Natalya Mill
- Date: Aug 2024
- Competency: External Forces & Industry Knowledge
- Publication Name: Health Watch
- Topics: Health & Disability; Health & Disability>Health care; Public Policy